Raloxifene / Evista — New SERM Research Profile Added

Comprehensive research profile for raloxifene (Evista): mechanism of tissue-selective ER modulation, gynecomastia treatment superiority over tamoxifen, DVT risk, bloodwork monitoring, and why it is not a PCT agent.